Compare General Mills, Inc. (GIS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs IDEXX Laboratories, Inc. — how do they compare? General Mills, Inc. trades at $32.27 (market cap $17.43B), while IDEXX Laboratories, Inc. trades at $516.73 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.3× General Mills, Inc.'s market cap, and General Mills, Inc. pays a 7.49% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 106 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| GIS | IDXX | |
|---|---|---|
Market Cap | $17.43B | $40.43B |
Volume | 16,554,362 | 692,164 |
Sector | Consumer Staples | Health |
52-Week High | $49.36 | $766.68 |
52-Week Low | $31.67 | $504.70 |
Typical Hold Time | 106 Days | 46 Days |
Enterprise Value | $30.61B | $41.32B |
Dividend Yield | 7.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.09, up 1.01% with mixed technical signals showing bearish moving averages but neutral oscillators. The company faces fundamental challenges with a negative net income margin of -4.89% and ROE of -10.55% for 2026, though it maintains strong operating cash flow of $2.92B in 2025. Recent leadership transition to Dana McNabb as CEO and a $3B cost-saving initiative aim to stabilize performance amid declining revenues.
The stock presents a value opportunity with a low P/E of 9.23 and a 7.6% upside to the $36 consensus target, supported by a reliable dividend. However, risks include persistent margin pressures, high debt levels at 45% of assets, and competitive headwinds in the packaged foods sector. Analyst sentiment is cautious with 61% hold ratings, reflecting uncertainty around the turnaround strategy's execution.
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
